Author Archives: Vanda Pinto

Ofev or Esbriet Can Help Stabilize Lung Function in Advanced IPF

Decline in lung function is slower in people with advanced idiopathic pulmonary fibrosis (IPF) who start treatment with Ofev (nintedanib) or Esbriet (pirfenidone), although their risk of death remains considerably greater than those with mild to moderate disease, a study based on patient data reported. Data from patient…

Thirona Bio, MannKind Team for Potential New IPF Inhaled Therapy

Thirona Bio has teamed with MannKind Corporation to develop and test a potential inhaled treatment for fibrotic lung diseases, including idiopathic pulmonary fibrosis (IPF). FBM5712, which Thirona is working to advance as a possible topical treatment of skin fibrosis, will be modified and investigated by MannKind for its…

Cedars-Sinai, Rubedo Partner to Develop Targeted IPF Treatments

Rubedo Life Sciences announced that it has partnered with Cedars-Sinai Medical Center, also in California, to advance its idiopathic pulmonary fibrosis (IPF) program and conduct collaborative research. The biopharmaceutical’s IPF program focuses on developing senolytics, or small molecules that target harmful senescent cells. These cells increase inflammation, fibrosis…

Umbilical Cord Stem Cells Hold Potential in PF Treatment

Small extracellular vesicles (EVs) released from umbilical cord stem cells seem to carry molecules that can inhibit the TGF-beta signaling pathway and reduce tissue damage in the lungs of mice with pulmonary fibrosis (PF), a study shows. The findings support further research on stem cell-derived EVs as a potential…

IPF Worsens Prognosis in Lung Cancer Patients

Idiopathic pulmonary fibrosis (IPF) is associated with poorer prognosis in patients with lung cancer, a study shows. People with lung cancer showed a higher risk of dying if IPF was present. The findings also suggest that lung cancer treatments, such as chemotherapy, can contribute to poor clinical outcomes by…

MUC5B Mutation May Lengthen Life for IPF Patients on Anti-fibrotics

A variant of the MUC5B gene, known as the rs35705950 (T) allele, appears to lead to better survival in people with idiopathic pulmonary fibrosis (IPF) on anti-fibrotic treatment, a study reports. These findings highlight the potential usefulness of MUC5B genetic data in treating and managing these patients. The study,…

PulmoSIM Launched to Repurpose Medications for Rare Lung Conditions

VeriSIM Life has launched a pharmaceutical subsidiary called PulmoSIM Therapeutics (PulmoSIM) to search for new treatments for rare lung diseases. Using artificial intelligence, PulmoSIM’s goal is to assess which therapies previously approved by the U.S. Food and Drug Administration for certain conditions can be effective for the treatment of…